Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02280161 · ClinicalTrials.gov registry record
Germ-Line Mutations in Blood and Saliva Samples From Patients With Cancer
A clinical trial of Malignant Neoplasm, sponsored by Jonsson Comprehensive Cancer Center.
- Recruiting
- Registry status
- 2,000
- Enrollment target
- 1
- Study location
NCT02280161 is a study of Malignant Neoplasm that is actively recruiting participants, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 2,000 participants, above the 480-participant average among 59 other Malignant Neoplasm trials with a reported enrollment target (317% higher). The trial reports 1 study location across 1 state.
The verdict
NCT02280161, a study of Malignant Neoplasm, is actively recruiting participants, sponsored by Jonsson Comprehensive Cancer Center.
- RECRUITING
- Registry status
- 2,000 participants
- Enrollment target
- 1
- Study location
Study Summary
This research trial studies germ-line mutations in blood and saliva samples from patients with cancer. Studying samples of blood and saliva from patients with cancer in the laboratory may help doctors learn more about how inherited genetic mutations can affect cancer predisposition (an inherited increase in the risk of developing cancer), their impact on treatment response, and their role in cancer development.
Conditions Studied
Interventions
- OTHER cytology specimen collection procedure
Study Locations (1)
California
- Jonsson Comprehensive Cancer Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2014-09-16 |
| Est. Completion | 2027-09-16 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02280161
The ClinicalTrials.gov registry entry for NCT02280161 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 2,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 480-participant average among 59 other Malignant Neoplasm trials with a reported enrollment target (317% higher). The listed sponsor is Jonsson Comprehensive Cancer Center, which has 321 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Malignant Neoplasm appearing as the primary indexed condition, and to 1 intervention - of which cytology specimen collection procedure is the first listed.
NCT02280161 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02280161 about?
NCT02280161 is a clinical study titled "Germ-Line Mutations in Blood and Saliva Samples From Patients With Cancer". This research trial studies germ-line mutations in blood and saliva samples from patients with cancer. Studying samples of blood and saliva from patients with cancer in the laboratory may help doctors learn more about how inherited genetic mutations can affect cancer predisposition (an inherited inc...
What is the current status of trial NCT02280161?
This trial is currently recruiting. The enrollment target is 2,000 participants. The study started on 2014-09-16. Estimated completion is 2027-09-16.
What conditions does trial NCT02280161 study?
This clinical trial studies the following conditions: Malignant Neoplasm.
What interventions are being tested in trial NCT02280161?
The interventions under investigation include: cytology specimen collection procedure (OTHER).
Who is sponsoring clinical trial NCT02280161?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02280161 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
RECRUITING · Phase 1
-
Pre-operative SRS or Post-operative SRS in Treating Cancer Patients With Brain Metastases
RECRUITING · Phase 3
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
Engagement of American Indians of Southwestern Tribal Nations in Cancer Genome Sequencing
RECRUITING · NA
-
A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)
RECRUITING · Phase 1
-
Norris ORIEN Total Cancer Care
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.